[
    [
        {
            "time": "2023-10-01",
            "original_text": "Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly",
            "features": {
                "keywords": [
                    "Q1",
                    "Earnings",
                    "Scorecard",
                    "Exxon",
                    "Oracle",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "energy",
                    "technology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Q1 Earnings Scorecard and Analyst Reports for Exxon, Oracle & Eli Lilly",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "IMBRUVICA® (ibrutinib) Receives 11th FDA Approval",
            "features": {
                "keywords": [
                    "IMBRUVICA",
                    "ibrutinib",
                    "FDA",
                    "Approval"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "IMBRUVICA® (ibrutinib) Receives 11th FDA Approval",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Allergan’s Acquisition by AbbVie Will Close Soon. Why One Analyst Just Downgraded Its Stock.",
            "features": {
                "keywords": [
                    "Allergan",
                    "AbbVie",
                    "Acquisition",
                    "Downgraded",
                    "Stock"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Allergan’s Acquisition by AbbVie Will Close Soon. Why One Analyst Just Downgraded Its Stock.",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "8 Safe High-Yield Dividend Stocks Offering 5% or More",
            "features": {
                "keywords": [
                    "Safe",
                    "High-Yield",
                    "Dividend",
                    "Stocks"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "diversified"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "8 Safe High-Yield Dividend Stocks Offering 5% or More",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Form 8.3 - ABBVIE PLC",
            "features": {
                "keywords": [
                    "Form 8.3",
                    "ABBVIE",
                    "PLC"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Form 8.3 - ABBVIE PLC",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "AbbVie Stock Falls 3%",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Stock",
                    "Falls"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Stock Falls 3%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 9,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "AbbVie - A Top Choice for a Post-Virus Portfolio",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Top",
                    "Choice",
                    "Post-Virus",
                    "Portfolio"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie - A Top Choice for a Post-Virus Portfolio",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-01",
            "original_text": "Form 8.3 - AbbVie Inc.",
            "features": {
                "keywords": [
                    "Form 8.3",
                    "AbbVie",
                    "Inc."
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Form 8.3 - AbbVie Inc.",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]